Mar 6, 2013 by Dave WilliamsonWhy Depomed Isn't Worth the RiskThis FDA approval bet is a real long shot.
Mar 5, 2013 by Dave WilliamsonThis Biotech's Run Is Far From DoneTwo pieces of news that show Gilead still has plenty of room to run.
Mar 4, 2013 by Dave WilliamsonCelgene Trial Disappointment No DisasterTrial results for Celgene's new drug weren't as good as hoped, but they aren't catastrophic.
Mar 1, 2013 by Dave WilliamsonMylan Just Got More InterestingOne acquisition that makes this biotech a much tastier investment.
Feb 27, 2013 by Dave WilliamsonVertex Enters Critical PhaseVertex begins one of the most critical trials of the company's history.
Feb 27, 2013 by Dave WilliamsonIs Zoegenix on the Verge of FDA Approval?Is FDA approval only weeks away for Zoegenix?
Feb 27, 2013 by Dave WilliamsonCan Optimer Optimize Shareholder Returns?Optimer looks at some "strategic" moves.
Feb 5, 2013 by Dave WilliamsonJanuary Top 10: KeryxA look back at January's most incredible health-care stocks.
Feb 5, 2013 by Dave WilliamsonJanuary Top 10: FuriexA look back at January's most incredible health-care stocks.
Feb 5, 2013 by Dave WilliamsonJanuary Top 10: MAP PharmaceuticalsA look back at January's most incredible health care stocks.
Feb 5, 2013 by Dave WilliamsonJanuary Top 10: CorceptA look back at January's most incredible health-care stocks.
Jan 31, 2013 by Dave WilliamsonFoolish Preview: Gilead EarningsA look ahead at what we can expect from Gilead.
Jan 31, 2013 by Dave WilliamsonZoetis: The Next Big IPOThe biggest IPO since Facebook is happening tomorrow.
Jan 31, 2013 by Dave WilliamsonA Broken HALO for Wall Street?Who will win out on Halozyme -- the bulls or the bears?
Jan 30, 2013 by Dave WilliamsonFoolish Review: Vertex EarningsA look at how Vertex performed this quarter.
Jan 29, 2013 by Dave WilliamsonFoolish Review: Pfizer EarningsPfizer's surprising upside, even without Lipitor.
